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Ainhoa Oñatibia-Astibiaa,b,∗, Amaia Malet-Larreaa, Amaia Mendizabalc,
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Objective:  To  estimate  the  effectiveness  of  a  Medication  Discrepancy  Detection  Service  (MDDS),
a collaborative  service  between  the  community  pharmacy  and  Primary  Care.
Design: Non-controlled  before-and-after  study.
Setting:  Bidasoa  Integrated  Healthcare  Organisation,  Gipuzkoa,  Spain.
Participants:  The  service  was  provided  by  a  multidisciplinary  group  of  community  pharmacists
(CPs), general  practitioners  (GPs),  and  primary  care  pharmacists,  to  patients  with  discrepancies
between  their  active  medical  charts  and  medicines  that  they  were  actually  taking.
Outcomes:  The  primary  outcomes  were  the  number  of  medicines,  the  type  of  discrepancy,  and
GPs’ decisions.  Secondary  outcomes  were  time  spent  by  CPs,  emergency  department  (ED)  visits,
hospital admissions,  and  costs.
Results:  The  MDDS  was  provided  to  143  patients,  and  GPs  resolved  discrepancies  for  126
patients. CPs  identified  259  discrepancies,  among  which  the  main  one  was  patients  not  tak-
ing medicines  listed  on  their  active  medical  charts  (66.7%,  n  =  152).  The  main  GPs’  decision  was
to withdraw  the  treatment  (54.8%,  n  =  125),  which  meant  that  the  number  of  medicines  per
patient was  reduced  by  0.92  (9.12  ±  3.82  vs.  8.20  ±  3.81;  p  <  .0001).  The  number  of  ED  visits
and hospital  admissions  per  patient  were  reduced  by  0.10  (0.61  ±  .13  vs  0.52  ±  0.91;  p  =  .405
and 0.17  (0.33  ±  0.66  vs.  0.16  ±  0.42;  p  =  .007),  respectively.  The  cost  per  patient  was  reduced
by D  444.9  (D  1003.3  ±  2165.3  vs.  D  558.4  ±  1273.0;  p  =  .018).∗ Corresponding author.
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Conclusion:  The  MDDS  resulted  in  a  reduction  in  the  number  of  medicines  per  patients  and
number of  hospital  admissions,  and  the  service  was  associated  with  affordable,  cost-effective
ratios.
© 2020  The  Authors.  Published  by  Elsevier  España,  S.L.U.  This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PALABRAS  CLAVE






Servicio  de  detección  de  discrepancias  de  la  medicación:  un  estudio  multidisciplinar
y  coste-efectivo
Resumen
Objetivos:  Estimar  la  efectividad  del  servicio  de  detección  de  discrepancias  de  la  medicación,
un servicio  de  colaboración  entre  la  farmacia  comunitaria  y  la  atención  primaria.
Diseño: Estudio  de  intervención  antes-después,  sin  grupo  control.
Emplazamiento:  Organización  Sanitaria  Integrada  de  Bidasoa,  Gipuzkoa,  España.
Participantes:  El  servicio  fue  ofrecido  por  un  grupo  multidisciplinar  que  incluía  farmacéu-
ticos comunitarios  (FC),  médicos  de  atención  primaria  (MAP)  y  farmacéuticos  de  atención
primaria a  pacientes  que  presentaban  discrepancias  entre  la  medicación  prescrita  en  la  hoja
de tratamiento  activo  y  lo  que  realmente  estaban  tomando.
Mediciones  principales:  Las  variables  principales  del  estudio  fueron  el  número  de  medicamen-
tos, tipo  de  discrepancia  y  la  decisión  del  MAP.  Las  variables  secundarias  fueron  tiempo  invertido
por el  farmacéutico,  visitas  al  servicio  de  urgencias,  ingresos  hospitalarios  y  los  costes.
Resultados:  El  servicio  se  ofreció  a  143  pacientes,  y  el  MAP  resolvió  las  discrepancias  de  un  total
de 126  pacientes.  El  FC  identificó  259  discrepancias  de  las  cuales  la  mayoría  fue  que  el  paciente
no estaba  tomando  un  medicamento  prescrito  (66,7%,  n  =  152).  En  la  mayoría  de  los  casos,  la
decisión  del  MAP  fue  suspender  el  tratamiento  (54,8%,  n  =  125);  el  número  de  medicamentos  que
tomaba el  paciente  se  redujo  en  un  0,92  (9,12  ±  3,82  vs.  8,20  ±  3,81;  p  <  0,0001).  El  número  de
visitas al  hospital  y  los  ingresos  hospitalarios  se  redujeron  en  0,10  (0,61  ±  0,13  vs.  0,52  ±  0,91;
p =  0,405)  y  0,17  puntos  (0,33  ±  0,66  vs.  0,16  ±  0,42;  p  =  0,007),  respectivamente.  El  coste  por
paciente se  redujo  en  444,9  D  (1.003,3  ±  2.165,3  vs.  558,4  D  ±  1.273,0;  p  =  0,018).
Conclusión:  El  servicio  redujo  el  número  de  medicamentos  que  tomaba  el  paciente  e  ingresos
hospitalarios  y  esto  se  relacionó  con  unos  ratios  de  coste-efectividad  positivos.
© 2020  Los  Autores.  Publicado  por  Elsevier  España,  S.L.U.  Este  es  un  art́ıculo  Open  Access  bajo






































edication  errors  (ME)  are  among  the  top  10  causes  of  death
orldwide.1 Such  errors  can  cause  patient  safety  incidents,
hich  are  associated  with  a  higher  rate  of  hospitalisation
nd  increased  morbidity  and  mortality,  accounting  for  more
han  1%  of  total  global  health  expenditures.2 ME  is  the  sin-
le  most  common  preventable  cause  of  adverse  events  in
edication  practice  and  a  major  public  health  burden,  with
n  estimated  annual  cost  in  Europe  of  D  4.5  billion  to  D  21.8
illion.3 Due  to  the  health  and  economic  impact  of  ME,  the
orld  Health  Organisation  (WHO)  has  included  the  reduction
f  ME  in  the  Global  Patient  Safety  Challenge.4
ME  has  been  defined  as  ‘any  preventable  event  that  may
ause  or  lead  to  inappropriate  medication  use  or  patient
arm  while  the  medication  is  in  the  control  of  the  health
are  professional,  patient,  or  consumer’.5 Contributing  fac-
ors  may  be  associated  with  health  care  professionals,
atients,  the  work  environment,  medicines,  comput-
rised  information  systems,  and/or  primary--secondary  care
ommunication.6 Reducing  the  frequency  and  impact  of  pre-





rror,  accident,  or  communication  problem  will  contribute
o  the  achievement  of  medication  safety  for  patients.7
tatistics  show  that  these  strategies  will  lead  to  95,000
ewer  deaths  per  year  in  Europe.2
Various  strategies  to  reduce  ME  in  the  community  set-
ing  have  been  proposed  in  recent  years;  they  include
edication  review  and  reconciliation  services,  the  use
f  automated  information  systems,  education,  and  multi-
omponent  interventions.8--10 The  effectiveness  of  clinical
harmacists  in  identifying  ME  has  been  demonstrated,  but
ata  from  primary  care  are  relatively  scarce  and  few  studies
ave  included  community  pharmacists  (CPs).11--13 This  lack
f  research  among  CPs  and  the  previous  experience  that
hese  professionals  have  in  other  services14 have  led  the
HO  to  consider  the  involvement  of  CPs  in  the  prioritisation
f  strategies  to  reduce  ME  in  primary  care.6
In  this  context,  to  meet  the  need  for  high-quality  and
ost-effective  identification  of  medication  discrepancies, medication  discrepancy  detection  service  (MDDS)  was
esigned.  To  ensure  patient-centred  care,  collaboration
mong  different  health  professionals  is  needed.15 The  MDDS




























































The  medication  discrepancy  detection  service  
general  practitioners  (GPs)  in  collaboration  with  primary
care  pharmacists  and  primary  care  nurses.  The  identification
of  medication  discrepancies  is  a  way  to  detect  ME,  and  CPs  in
Spain  are  ideally  positioned  to  do  so,  as  they  have  access  to
electronic  medical  records  and  are  responsible  for  dispens-
ing  medicines.  Therefore,  the  aim  of  the  present  study  was
to  evaluate  the  impact  on  the  number  of  medicine  intake
and  the  cost  effectiveness  of  the  MDDS  as  implemented  col-
laboratively  in  the  community  pharmacy  and  primary  care
services  settings.
Methods
Study  design  and  ethical  approval
This  non-controlled  before-and-after  study.was  undertaken
between  October  2015  and  September  2016  in  the  Bidasoa
Integrated  Healthcare  Organisation,  Spain,  which  is  com-
prised  of  one  regional  hospital  and  three  primary  care  units.
The  multidisciplinary  professional  group  that  provided  the
MDDS  consisted  of  CPs,  primary  care  pharmacists,  GPs,  and
hospital  specialists.  All  the  CPs  of  the  pharmacies  located
in  the  municipalities  attended  by  the  Integrated  Healthcare
Organisation,  were  invited  to  participate  in  the  project.  CPs
and  GPs  attended  a  2-hour  workshop  that  presented  and
described  the  study  protocol.  The  protocol  for  this  study
was  approved  by  the  Ethics  Committee  for  Clinical  Research
of  the  Basque  Country  (PI2015080  EPA-SP)  and  was  in  line
with  the  Helsinki  Declaration.  All  participants  provided  writ-
ten  informed  consent  at  the  time  of  their  enrolment,  and
CPs  delivered  information  sheets  explaining  the  study  to
patients  who  met  the  study  criteria.
Patients
Patients  were  recruited  according  the  following  criteria:
patients  that  had  a  discrepancy  between  their  active  medi-
cal  charts  and  the  medicines  they  were  actually  taking.  CP
identified  this  patients  with  discrepancies  like  (i)  patients
not  taking  medications  that  appeared  in  their  charts,  (ii)  tak-
ing  medications  that  did  not  appear  in  their  charts,  (iii)  not
following  the  prescribed  dosage  regime,  (iv)  not  following
the  prescribed  posology  and  (v)  duplicated  treatment.
Study  procedure  and  health  outcomes
CPs  offered  the  MDDS  service  to  patients  in  whom  at  the
time  of  dispensing  they  identified  a  discrepancy  between
their  active  medical  chart  and  the  medicines  they  were  tak-
ing.  CPs  registered  each  participating  patient’s  name,  health
identification  number,  willingness  to  participate  in  the  study,
and  date  of  first  appointment  (record  1).  Patients  were
asked  to  bring  all  current  medications,  including  dietary
and  other  products,  to  the  pharmacy.  The  CPs  performed
a  clinical  interviews  and  checked  brown  bags  For  the  inter-
view,  the  pharmacist  used  a  guide  consisting  of  structured
questions  that  allowed  to  collect  as  much  information  as
possible  about  taking  prescribed  medications,  other  medi-
cations,  supplements,  creams  or  other  products.  The  brown





Figure  1  Flowchart  of  the  study  procedure.
edications  taken  by  each  patient  based  on  the  medica-
ion  packages.  At  the  time  of  the  clinical  interview,  each
atient  provided  written  informed  consent.  If  a  patient  did
ot  return  for  the  scheduled  appointment,  it  was  recorded
s  ‘‘rejected’’.  After  the  clinical  interview,  the  information
as  compared  with  the  patient’s  medical  chart  and  the  CP
repared  a report  in  which  all  detected  discrepancies  were
egistered.  Once  the  CP  evaluated  the  patient’s  situation,
he  CP  completed  the  report  and  sent  it  to  the  primary
are  pharmacist.  Time  invested  in  the  clinical  interview  and
eport  preparation  was  also  registered.
Upon  receiving  the  report,  the  primary  care  pharmacist
ontacted  the  corresponding  primary  care  nurse,  who  cited
he  patient  with  the  GP.  The  GP  conducted  a  clinical  inter-
iew  and  was  responsible  for  making  any  necessary  changes
o  the  medical  chart  in  the  electronic  prescribing  system.  If
 medical  specialist  was  responsible  for  the  prescription,  the
rimary  care  pharmacist  contacted  directly  by  telephone
o  solve  the  problem.  Pharmacotherapeutic  changes  were
ade  in  agreement  with  the  patient,  and  the  GP  made  sure
hat  the  patient  understood  the  new  treatment  (Fig.  1).  Dis-
repant  medications  were  classified  using  the  Anatomical
herapeutic  Chemical  system.
Primary  care  pharmacists  compiled  and  recorded  all  data,
nd  were  responsible  for  registering  discrepancies  and  for
nsuring  that  the  flowchart  was  followed  correctly.  Emer-
ency  department  (ED)  visits  and  hospital  admissions  6
onths  before  and  after  the  intervention  were  registered
t  the  end  of  the  study  period  using  hospital  records.
conomic  outcomes
n  economic  evaluation  was  conducted  from  the  National
ealth  System  (NHS)  perspective.  The  cost  and  effectiveness
f  the  service  was  analysed.  The  direct  costs  of  medications
including  discrepant  medications),  ED  visits  and  hospital










































































nd  interventions  costs  were  included.  The  numbers  of
edicines,  ED  visits,  and  hospital  admissions  served  as
ffectiveness  variables.  Costs  were  estimated  using  posol-
gy  and  the  prices  of  the  medicines.  The  costs  associated
ith  ED  visits  were  estimated  based  on  the  Basque  Health
ervice  (BHS)  rates.16--18 The  diagnosis-related  group  (DRG)
as  identified  for  each  hospital  admission.  DRGs  make  up  an
stablished  payment  system  for  groups  of  patients  with  simi-
ar  clinical  characteristics  who  are  expected  to  have  similar
ealth  resource  consumption.4 The  cost  for  each  DRG  was
etermined  using  BHS  rates.16--19 The  total  cost  of  each  inter-
ention  included  costs  associated  with:  (i)  the  time  spent  by
he  CP  on  the  clinical  interview,  (ii)  the  time  spent  by  the  CP
o  complete  the  report,  (iii)  the  cost  of  GP  consultation  (iv)
he  cost  of  hospital  telephone  specialist  consultation  and
v)  the  cost  of  the  time  spent  by  primary  care  pharmacists.
osts  (i)  and  (ii)  were  estimated  using  collective  CP  bar-
aining  data.  Costs  (iii)  and  (iv)  were  estimated  using  BHS
ates.16 All  costs  were  expressed  in  euros  and  updated  to
017  using  the  Spanish  Retail  Price  Index.  The  incremental
ost-effectiveness  ratio  (ICER)  was  calculated  to  compare
osts  before  and  after  the  intervention.
tatistical  analysis
hanges  in  the  numbers  of  medicines,  ED  visits,  and  hospital
dmissions  were  evaluated  and  compared  before  and  after
DDS  implementation  with  the  paired  t  test  or  Student’s
 test  for  parametric  variables.  The  chi-squared  test  and
isher’s  exact  test  were  used  to  analyse  the  frequency  distri-
utions  of  the  study  variables.  A  one-way  sensitivity  analysis
as  conducted  to  examine  the  impacts  of  the  study  variables
n  the  results  of  the  economic  evaluation.  General  data  are
xpressed  as  means  ±  standard  deviations.  Statistical  anal-
ses  were  performed  using  the  SPSS  software  (version  18.0
or  Windows  XP;  Microsoft  Corporation,  Armonk,  NY,  USA).
wo-tailed  p  values  <  0.05  were  considered  to  be  statistically
ignificant.esults
en  of  the  30  community  pharmacies  located  in  the  munici-





Table  1  Numbers  of  medicines,  emergency  department  visits,  and
of medication  discrepancies  (n  =  126).
Variable  n x̄ (SD)  
Number  of  medicines
Before  1149  9.12  (3.82)  
After 1033  8.20  (3.81)
Number  of  ED  visits
Before  77  0.61  (1.13)  
After 65  0.52  (0.91)
Number  of  hospital  admissions
Before  41  0.33  (0.66)  
After 20  0.16  (0.42)
x̄, mean; SD, standard deviation; ED, emergency department.A.  Oñatibia-Astibia  et  al.
articipated  in  the  project  and  offered  the  MDDS  to  a  total
f  240  patients.  CPs  identified  259  discrepancies  in  143
atients,  leading  to  228  medication  reconciliations  for  126
atients  by  GPs  and  other  medical  specialists.  The  major-
ty  (72.3%)  of  participants  were  women  and  the  mean  age
as  72.3  ±  13.1  years.  The  mean  number  of  prescribed
edicines  take  was  9.1  ±  3.8  per  patient  and  the  mean  num-
er  of  medication  interventions  was  1.8  ±  1.3  per  patient.
The  main  type  of  discrepancy  registered  by  CPs  was  that
atients  were  not  taking  medicines  listed  on  their  active
edical  charts  (58.7%,  n  =  152).
In  more  than  half  (54.8%,  n =  125)  of  discrepancy  cases,
Ps  decided  to  withdraw  the  treatment.  In  other  cases,  the
reatment  was  not  modified  (24.6%,  n  =  56),  it  was  modi-
ed  (13.6%,  n  =  31),  or  new  treatment  was  initiated  (7.0%,
 =  16).  The  groups  of  medicines  with  the  most  discrepan-
ies  were  drugs  for  obstructive  airway  diseases  (R03;  8.3%,
 =  19),  psycholeptics  (N05;  8.3%,  n  =  18),  and  non-steroidal
nti-inflammatory  and  antirheumatic  products  (M01A;  7.5%,
 =  17).
After  the  intervention,  a  significant  reduction  in  the
umber  of  medicines  in  patients’  active  medical  charts
−0.92  ±  1.09,  p  <  0.0001)was  seen.  CPs  invested  an  average
f  11.8  ±  4.1  min  performing  each  initial  patient  interview
nd  13.8  ±  5.0  min  drafting  the  report.  They  thus  spent  a
ean  total  of  25.5  ±  7.4  min  per  patient  providing  the  ser-
ice.  Thirteen  cases  were  transferred  to  medical  specialists
ho  had  prescribed  discrepant  medicines.
The  number  of  hospital  admissions  decreased
−0.17  ±  0.68,  p  =  0.007)  after  MDDS  implementation
ompared  with  baseline  (Table  1).  The  number  of  ED  visits
lso  decreased,  but  this  difference  was  not  significant.
conomic  outcomes
he  mean  cost  of  the  intervention  was  D  71.5  ±  15.8.  GP
onsultations  were  the  costliest  components  (D  55  each)  fol-
owed  by  the  telephone  specialist  consultation  (50D  each);
he  average  costs  of  CP  and  specialist  consultations  were
 11.3  ±  3.3  and  D  5.2  ±  15.3,  respectively.  The  costs  of
edication,  ED  visits,  and  hospital  admissions  were  lower
fter  the  intervention  (Table  2).  Even  taking  into  account
 hospital  admissions  6  months  before  and  after  the  resolution
Difference: x̄ (SD)  p  value
−0.92  (1.09)  <0.0001
−0.10  (1.28)  0.405
−0.17  (0.68)  0.007
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Table  2  Mean  costs  per  patient  (D  ,  2017;  n  =  126).
Item  (SD)  Difference:  (SD)  p  value
Medication
Before  1.4  (3.0)  −0.77  (2.5)  <0.0001
After 0.6  (2.1)
ED visits
Before  92.3  (171.9)  −14.4  (193.3)  0.007
After 77.9  (138.7)
Hospital  admissions
Before  909.7  (2079.8) −501.2 (2001.9) <0.0001
After  408.4  (1229.6)
Intervention
Before  --  71.5  (15.8)  --
After 71.5  (15.8)
Total
Before  1003.3  (2165.3) −444.9  (2089.8)  0.018
After 558.4  (1273.0)
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Sensitivity analysis
Figure  2  Results  of  one-way  sensitivity  analysis  including
variables  critical  to  the  economic  evaluation.  CHospAdB,  cost
of hospital  admission  before  intervention;  CHospAAB,  cost  of
hospital  admission  after  intervention;  Nmedic,  number  of  medi-
































intervention;  CEDvisitsA,  cost  of  emergency  department  visits
after intervention;  Cinterv,  cost  of  intervention.
the  cost  of  the  intervention,  all  costs  were  lower  thereafter
(p  <  0.05).
For  all  three  cost-economic  variables,  the  intervention
was  cost  effective  because  health  outcomes  were  better  and
costs  were  lower.  The  sensitivity  analysis  showed  that  the
variable  with  the  greatest  impact  was  the  number  of  hospi-
tal  admissions,  as  it  was  the  only  variable  that  could  invert
the  cost.  All  other  variables  analysed  slightly  increased  or
decreased  the  benefits  obtained  with  the  service  (Fig.  2).
Discussion
This  study  showed  that  the  MDDS  is  an  effective  and  innova-
tive  way  to  detect  medication  discrepancies  in  community
pharmacies  and  to  resolve  them  with  the  collaboration  of
diverse  health  professionals,  such  as  CPs,  GPs,  other  medical
specialists  and  primary  care  pharmacists.  The  high  percent-





umber  of  drugs  taken  (by  almost  one  per  patient)  suggest
 significant  improvement  in  patient  safety.
CPs  identified  240  patients  with  medication  discrep-
ncies,  of  whom  143  accepted  study  participation.  The
ajority  of  these  143  patients  had  single  discrepan-
ies,  and  the  rest  had  discrepancies  in  more  than  one
edication.  Medication  discrepancies  can  be  detected  at
ifferent  levels.  Several  systematic  reviews  have  shown
hat  pharmacist-based  interventions  are  effective  in  the
ommunity  setting.20,21 The  MDDS  identifies  and  reduces
iscrepancies  being  the  particularity  of  this  study  the
nvolvement  of  all  health  agents,  especially  community
harmacists,  in  the  control  of  medication  errors.  Our  data
uggest  that  CPs  are  ideally  positioned  to  detect  medica-
ion  discrepancies,  in  agreement  with  the  WHO’s  strategy
o  include  CP  in  plans  to  detect  ME.6
Removing  a medication  from  the  medical  chart  was  the
ost  common  intervention  performed  by  the  GP.  It  has
een  demonstrated  that  after  the  MDDS  intervention,  each
atient  in  this  study  used,  on  average,  almost  one  fewer
edication  than  at  baseline.  Polypharmacy  is  related  to
oor  adherence,  interactions  and  ME,22 and  reducing  this
ondition  is  included  in  the  WHO’s  third  Global  Patient
afety  Challenge.7 Thus,  the  MDDS  could  provide  a  strat-
gy  for  the  reduction  of  polypharmacy-related  problems.
urthermore,  this  service  represents  that  it  could  be  an
fficient  way  of  improving  patients’  medication-related
afety  and  a  strategy  to  prevent  and  manage  patients’
railty.23
One  problem  associated  with  medication  reconcilia-
ion  interventions  for  CPs  is  the  difficulty  of  contacting
hysicians.24 Several  authors  have  stated  that  future  ini-
iatives  should  focus  on  collaboration  between  health  care
rofessionals,  and  such  collaboration  is  also  essential  when
esigning  services.25,26 Therefore,  CPs  and  primary  care
harmacists  participated  in  the  design  of  the  MDDS.  Primary
are  pharmacists  served  as  intermediaries  between  CPs  and




















































































The  numbers  of  hospital  admissions  and  ED  visits  were
5%  and  16%  lower,  respectively,  after  the  intervention  than
t  baseline.  Similar  reductions  have  been  observed  after
linical  pharmacists-based  interventions.27,28 Due  to  the  use
f  a  wide  range  of  methods  to  calculate  the  cost  of  ME,
alculation  of  the  worldwide  health  care  expenditure  associ-
ted  with  hospital  admissions  and  ED  visits  due  to  such  error
s  difficult.29 However,  authors  agree  that  this  cost  is  high.30
 study  conducted  in  the  Netherlands  showed  that  the
ost  of  hospital  admission  due  to  preventable  medication-
elated  events  increased  to  D  3171  per  patient,  and  ED  visits
ccounted  for  D  30,896,  or  5.3%  of  the  total  health  costs,
uring  the  study  period.31 One  objective  of  the  Organisation
or  Economic  Co-operation  and  Development  in  2014  was  to
dentify  good  practices  in  managing  health  care  budgets.32
herefore,  reducing  hospital  admissions  and  ED  visits  with
he  MDDS  could  contribute  to  improving  the  sustainability  of
he  health  system.
Our  analysis  supports  the  hypothesis  that  the  MDDS  is
 dominant  intervention,  as  it  improves  clinical  outcomes
ith  lower  costs  than  usual  care,  regardless  of  the  cost
f  the  intervention  itself.  The  sensitivity  analysis  showed
hat  only  the  cost  related  to  hospital  admissions  could
nvert  the  ICER.  The  variability  in  the  cost  of  such  admis-
ions  is  greater  than  variabilities  for  other  health  outcomes.
ome  authors  have  stated  that  use  of  the  DRG  system
ay  lead  to  inequities  in  associated  costs.26 To  reduce
his  variability,  the  identification  of  hospital  admissions
elated  to  medicines  and  exclusion  of  unrelated  admission
rom  analysis  could  be  useful.33 Previous  economic  evalu-
tions  have  focused  on  transitional  care  programmes  that
ncluded  interventions  to  prevent  ME  among  settings,  and
hey  have  produced  variable  results.34--37 Recent  evaluations
ave  shown  that  the  services  provided  by  CPs  tend  to  be  cost
ffective.38,39 The  implementation  of  professional  pharmacy
ervices  like  the  MDDSmay  be  an  efficient  way  to  improve
atient  safety.
The  groups  of  medicaments  with  the  most  discrep-
ncies  in  this  study  were  drugs  for  obstructive  airway
iseases  (R03),  psycholeptics  (N05),  and  non-steroidal
nti-inflammatory  and  antirheumatic  products  (M01A).  Con-
idering  that  most  discrepancies  detected  in  this  study  were
ue  to  patients  not  taking  medicines  included  in  their  medi-
al  charts  we  could  state  that  patients’  more  frequently
ave  adherent  problems.  Patients  with  medicines  prescribed
or  obstructive  airway  diseases,  psycholeptics  and  non-
teroidal  anti-inflammatory  and  antirheumatic  products  are
ne  of  the  most  prevalent  groups  of  patients  to  have
dherent  problems.40 Although  CPs  should  be  aware  of  dis-
repancies  in  all  types  of  medication,  special  attention  must
e  given  to  these  medication  groups  when  providing  the
DDS.
The  present  study  has  several  limitations.  Firstly,  it
as  conducted  within  the  Bidasoa  Integrated  Healthcare
rganisation,  and  a  relatively  small  number  of  patients  par-
icipated.  To  increase  the  external  validity  of  our  findings,
he  study  should  be  replicated  in  other  regions.  Sencondly,
nly  patients  in  the  NHS  are  eligible  for  the  MDDS,  as  they
re  the  only  ones  for  whom  CPs  receive  electronic  pres-
ription  information.  However,  the  authors  do  not  believe
hat  the  inclusion  of  the  entire  target  population  would
lter  the  results.  Thirdly,  the  present  study  included  no
R
A.  Oñatibia-Astibia  et  al.
andom  assignment  or  control  group,  and  the  modifica-
ions  observed  could  be  attributed  to  factors  other  than
he  intervention.  To  increase  the  reliability  of  the  MDDS
nd  our  finding  that  it  is  cost  effective  compared  with
sual  care,  the  results  of  this  study  should  be  compared
n  studies  conducted  with  control  groups.  Finally,  all  hospi-
al  admissions  and  ED  visits  were  included  in  analysis,  with
o  evaluation  of  cause.  To  minimise  possible  bias,  future
nalyses  should  include  only  hospital  admissions  and  ED
isits  associated  with  ME.  Future  health  policies  must  pro-
ide  support  for  the  development  and  implementation  of
vidence-based  services  to  prevent  ME  and  improve  patient
afety.
What was known?
•  The  reduction  of  preventable  harms  related  to
medicines  will  reduce  patient  safety  incidents.
•  Community  and  primary  care  pharmacists  are  useful
health  professionals  in  efforts  to  reduce  medication
errors  in  primary  care.
What is new?
•  The  MDDS  might  reduce  the  numbers  of  medications
prescribed,  emergency  department  visits,  and  hos-
pital  admissions.
• The  MDDS  might  be  a cost-effective  service  that
could  contribute  to  improving  the  sustainability  of
the  health  system.
•  The  MDDS  might  be  effective  as  a  collaborative
approach  between  the  community  pharmacy  and
ambulatory  settings.
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